Orgenesis Enters Asset Purchase Agreement With Broaden Bioscience For CAR-T Processing Assets; Will Pay Up To $11M Based On Third Party Valuation; Payment Exceeding $10.77M Debt May Be Made In Shares Or A Note With 24-Month Amortization
Orgenesis Enters Asset Purchase Agreement With Broaden Bioscience For CAR-T Processing Assets; Will Pay Up To $11M Based On Third Party Valuation; Payment Exceeding $10.77M Debt May Be Made In Shares Or A Note With 24-Month Amortization
Orgenesis與Broaden Bioscience簽訂資產購買協議，涉及CAR-t處理資產，將根據第三方估值支付高達1100萬美元，超過1077萬美元的債務可以選擇通過股票或24個月分期攤銷的票據進行支付。
Orgenesis Enters Asset Purchase Agreement With Broaden Bioscience For CAR-T Processing Assets; Will Pay Up To $11M Based On Third Party Valuation; Payment Exceeding $10.77M Debt May Be Made In Shares Or A Note With 24-Month Amortization
Orgenesis與Broaden Bioscience簽訂資產購買協議，涉及CAR-t處理資產，將根據第三方估值支付高達1100萬美元，超過1077萬美元的債務可以選擇通過股票或24個月分期攤銷的票據進行支付。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。